Takahisa Kanekiyo

List of Publications by Year
in descending order

64	7,850	87888	102487
papers	citations	38 h-index	66 g-index

69	69	69	11523
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 2013, 9, 106-118.	10.1	2,482
2	ApoE and AÎ² in Alzheimerâ€™s Disease: Accidental Encounters or Partners?. Neuron, 2014, 81, 740-754.	8.1	460
3	Central role for PICALM in amyloid-Î² blood-brain barrier transcytosis and clearance. Nature Neuroscience, 2015, 18, 978-987.	14.8	334
4	Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2017, 18, 1965.	4.1	273
5	Neuronal Clearance of Amyloid-Î² by Endocytic Receptor LRP1. Journal of Neuroscience, 2013, 33, 19276-19283.	3.6	206
6	The low-density lipoprotein receptor-related protein 1 and amyloid-ÃŽÂ² clearance in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 93.	3.4	199
7	Astrocytic LRP1 Mediates Brain AÎ² Clearance and Impacts Amyloid Deposition. Journal of Neuroscience, 2017, 37, 4023-4031.	3.6	175
8	LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-Î². Journal of Neuroscience, 2012, 32, 16458-16465.	3.6	174
9	Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. Journal of Lipid Research, 2017, 58, 1267-1281.	4.2	174
10	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimerâ€™s disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	12.8	172
11	Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimerâ€™s Disease. Neuron, 2014, 84, 63-77.	8.1	168
12	Vascular Cell Senescence Contributes to Bloodâ€“Brain Barrier Breakdown. Stroke, 2016, 47, 1068-1077.	2.0	167
13	APOE Îµ4/Îµ4 diminishes neurotrophic function of human iPSC-derived astrocytes. Human Molecular Genetics, 2017, 26, 2690-2700.	2.9	162
14	The role of APOE in cerebrovascular dysfunction. Acta Neuropathologica, 2016, 131, 709-723.	7.7	161
15	Alzheimerâ€™s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron, 2020, 106, 727-742.e6.	8.1	152
16	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. Brain, 2019, 142, 1077-1092.	7.6	120
17	ApoE Cascade Hypothesis in the pathogenesis of Alzheimerâ€™s disease and related dementias. Neuron, 2022, 110, 1304-1317.	8.1	120
18	Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-Î² clearance and aggregation in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 332ra44.	12.4	115

#	Article	IF	Citations
19	Neuronal LRP1 Regulates Glucose Metabolism and Insulin Signaling in the Brain. Journal of Neuroscience, 2015, 35, 5851-5859.	3.6	110
20	ABCA7 Deficiency Accelerates Amyloid-Î² Generation and Alzheimer's Neuronal Pathology. Journal of Neuroscience, 2016, 36, 3848-3859.	3.6	109
21	LRP1 modulates the microglial immune response via regulation of JNK and NF-ÎºB signaling pathways. Journal of Neuroinflammation, 2016, 13, 304.	7.2	101
22	APOE4-mediated amyloid-Î² pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	8.2	96
23	Apolipoprotein E as a Therapeutic Target in Alzheimerâ€™s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 2016, 30, 773-789.	5.9	93
24	Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. Journal of Controlled Release, 2018, 286, 264-278.	9.9	88
25	Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease. EBioMedicine, 2015, 2, 294-305.	6.1	87
26	ABCA7 and Pathogenic Pathways of Alzheimerâ€™s Disease. Brain Sciences, 2018, 8, 27.	2.3	87
27	APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Annals of Neurology, 2016, 79, 758-774.	5.3	77
28	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 225-234.	7.7	73
29	Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway. Journal of Biological Chemistry, 2014, 289, 11282-11292.	3.4	62
30	Modeling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells. Tissue Engineering - Part A, 2018, 24, 1125-1137.	3.1	55
31	Pericyte implantation in the brain enhances cerebral blood flow and reduces amyloid-Î² pathology in amyloid model mice. Experimental Neurology, 2018, 300, 13-21.	4.1	53
32	Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties . International Journal of Nanomedicine, 2019, Volume 14, 6497-6517.	6.7	51
33	Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Experimental Neurology, 2016, 277, 1-9.	4.1	50
34	Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway. Journal of Biological Chemistry, 2015, 290, 14208-14217.	3.4	49
35	ApoE-2 Brain-Targeted Gene Therapy Through Transferrin and Penetratin Tagged Liposomal Nanoparticles. Pharmaceutical Research, 2019, 36, 161.	3.5	48
36	Apolipoprotein E lipoprotein particles inhibit amyloid-Î² uptake through cell surface heparan sulphate proteoglycan. Molecular Neurodegeneration, 2016, 11, 37.	10.8	45

#	Article	IF	Citations
37	ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 128-144.	2.4	45
38	ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23790-23796.	7.1	43
39	Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron, 2021, 109, 438-447.e6.	8.1	42
40	Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes. Brain Research, 2020, 1734, 146738.	2.2	41
41	Functionalized liposomal nanoparticles for efficient gene delivery system to neuronal cell transfection. International Journal of Pharmaceutics, 2019, 566, 717-730.	5.2	38
42	Partial inhibition of mitochondrial complex I ameliorates Alzheimerâ€™s disease pathology and cognition in APP/PS1 female mice. Communications Biology, 2021, 4, 61.	4.4	35
43	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.8	34
44	Tyrosine-based Signal Mediates LRP6 Receptor Endocytosis and Desensitization of Wnt/Î²-Catenin Pathway Signaling. Journal of Biological Chemistry, 2014, 289, 27562-27570.	3.4	33
45	APOE2 is associated with longevity independent of Alzheimerâ€™s disease. ELife, 2020, 9, .	6.0	33
46	Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 354-365.	2.5	31
47	Differential Effects of Extracellular Vesicles of Lineage-Specific Human Pluripotent Stem Cells on the Cellular Behaviors of Isogenic Cortical Spheroids. Cells, 2019, 8, 993.	4.1	29
48	Elevated Neutrophil-Lymphocyte Ratio is Predictive of Poor Outcomes Following Aneurysmal Subarachnoid Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104631.	1.6	29
49	Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Regulates the Stability and Function of GluA1 Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) Receptor in Neurons. PLoS ONE, 2014, 9, e113237.	2.5	28
50	Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice. Neurobiology of Aging, 2017, 53, 112-121.	3.1	26
51	Nerve Growth Factor Gene Delivery across the Bloodâ€“Brain Barrier to Reduce Beta Amyloid Accumulation in AD Mice. Molecular Pharmaceutics, 2020, 17, 2054-2063.	4.6	25
52	Apolipoprotein E regulates lipid metabolism and Î±-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	7.7	25
53	In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102225.	3.3	23
54	Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2021, 79, 335-353.	2.6	22

#	Article	IF	Citations
55	Identification of plexin A4 as a novel clusterin receptor links two Alzheimerâ€™s disease risk genes. Human Molecular Genetics, 2016, 25, 3467-3475.	2.9	21
56	Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. International Journal of Biological Macromolecules, 2022, 208, 901-911.	7.5	19
57	Multiple system atrophy and apolipoprotein E. Movement Disorders, 2018, 33, 647-650.	3.9	15
58	5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway. International Journal of Molecular Sciences, 2019, 20, 1488.	4.1	14
59	ABCA7 Regulates Brain Fatty Acid Metabolism During LPS-Induced Acute Inflammation. Frontiers in Neuroscience, 2021, 15, 647974.	2.8	12
60	Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 93.	5.2	9
61	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology, 2022, 98, .	1.1	7
62	Mesenchymal stem cell therapy for focal epilepsy: A systematic review of preclinical models and clinical studies. Epilepsia, 2022, 63, 1607-1618.	5.1	7
63	Generation and validation of APOE knockout human iPSC-derived cerebral organoids. STAR Protocols, 2021, 2, 100571.	1.2	4
64	Counteracting Alzheimerâ€™s disease via somatic TERT activation. Nature Aging, 2021, 1, 1081-1082.	11.6	1